Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
CMTA-STAR Awards $354,826 for CMT Clinical Trial
…CMT. Most people (90%) have one of four types of CMT: CMT 1A (PMP22); CMT 1B (MPZ); CMT 2A (MFN2) and CMT 1X (GJB1). It is estimated that CMT affects…
STAR: Our CMT Research Strategy
…more about how the CMT is accelerating research for Demyelinating and Axonal forms of CMT READ MORE: DEMYELINATING CMT ⟶ READ MORE: AXONAL CMT ⟶ Last Updated: November 12, 2024…
2021_Spring_CMTA_Report
NMD Pharma Receives FDA Approval to Initiate Phase II Clinical Trial of NMD670 in CMT Patients
…clinical trial for their investigational drug, NMD670, in patients with Charcot-Marie-Tooth disease (CMT). This trial, named SYNAPSE-CMT, marks a significant milestone in the journey towards finding effective treatments for CMT….
CMTA-STAR Research for Axonal Forms of CMT
…in-depth conversation about STAR please reach out to Jeana Sweeney, Chief Engagement and Gift Officer: jeana@cmtausa.org. Support CMT Research READ MORE ABOUT CMTA-STAR RESEARCH FOR AXONAL TYPES OF CMT CMT…
CMT2A Research
CMT2A CMT2A is caused by dominant mutations in Mitofusin 2 (MFN2). The STAR team has developed two excellent rat models for CMT2A which are being made available to the research…
CMTA Report Fall 2021
2021_Winter_CMTA_Report
X-linked CMT
…CMT1X/X1 is the second most common CMT subtype, accounting for approximately 17% of all CMT cases, second only to CMT1A, which accounts for approximately 60% of all CMT cases. The…
CMTA Invests $210K in Long-Read Sequencing to Accelerate CMT Gene Discovery
…University College London, this new CMTA Strategy To Accelerate Research (CMTA-STAR) initiative will apply long-read genome sequencing to search for hidden genetic causes of CMT. As many as 50% of…